A small-molecule activator of ULK1 that induces cytoprotective autophagy for Parkinson disease treatment

2017-01-16 03:42LanZHANGDahongYAOGuanWANG
中国药理学与毒理学杂志 2017年10期

Lan ZHANG,Da-hong YAO,Guan WANG

(State Key Laboratory of Biotherapy and Cancer Center,West China Hospital,Sichuan University,and Collaborative Innovation Center of Biotherapy,Chengdu 610041,China)

T1-42

A small-molecule activator of ULK1 that induces cytoprotective autophagy for Parkinson disease treatment

Lan ZHANG,Da-hong YAO,Guan WANG

(State Key Laboratory of Biotherapy and Cancer Center,West China Hospital,Sichuan University,and Collaborative Innovation Center of Biotherapy,Chengdu 610041,China)

OBJECTIVETo discover a small-molecule activator of ULK1 for Parkinson disease treatment and exploreits potential mechanisms.METHODSCandidate ULK1 activator was found by using structure-based design and high-through put screening,then modified by chemical synthesis and screened by kinase and autophgic activities.The amino acid residues that key to the activation site of the best candidate ULK1 activator(BL-918)were determined by site-directed mutagenesis,as well as in vitro kinase assay,ADP-Glo kinase assay and surface plasmon resonance(SPR)analysis.The mechanisms of BL-918 induced cytoprotective autophagy were investigated by electron microscopy,fluorescence microscopy,Western blotting,co-immunoprecipitation assay,siRNA and GFP-LC3 plasmid transfections.The therapeutic effect of BL-918 was determined by MPTP-mouse model,including behavioral tests,the levels of dopamine and its derivatives,as well as immunofluorescence and Western blotting.The toxicity of BL-918 was assessed by blood sample analysis and hematoxylin-eosin staining.RESULTSWe discovered a small molecule(BL-918)as a potent activator of ULK1 by structure-based drug design.Subsequently,some key amino acid residues(Arg18,Lys50,Asn86 and Tyr89)were found to be crucial to the binding pocket between ULK1 and BL-918,by site-directed mutagenesis.Moreover,we found that BL-918 could induce autophagy via the ULK complex in neuroblastoma SH-SY5Y cells.Intriguingly,this activator displayed a cytoprotective effect on MPP+-treated SH-SY5Y cells,as well as protected against MPTP-induced motor dysfunction and loss of dopaminergic neurons by targeting ULK1-modulated autophagy in mouse models of PD.CONCLUSIONWe discovered a novel ULK1 activator(BL-918)that potently activated ULK1.This activator could induce cytoprotective autophagy via the ULK1 complex in SH-SY5Y cells,and also exerted its neuroprotective effects by targeting ULK1-modulated autophagy in a MPTP-induced PD mouse model,which may serve as a candidate drug for future PD therapy.

autophagy;Parkinson disease;UNC-51-like kinase 1;ULK1 activator;ULK complex

The project supported by National Natural Science Foundation of China(81602953);China Post⁃doctoral Special Science Foundation(2017T100706);and China Postdoctoral Science Foundation(2016M590893)

Lan ZHANG,Tel:18583220845,E-mail:zhanglanx_9@126.com